Serum CA-125 and HE4 levels are considered clinical predictors of survival and treatment response in patients with EOC, but there is no conclusive evidence on whether serum tumor markers are predictive of LNM, and they vary widely between different study populations [29, 30]. This evidence concerns the gene WFDC2 and neoplasm.